awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38194159-8FB5CC96-4B41-4919-AA09-E4D65A316D6B
Q38194159-8FB5CC96-4B41-4919-AA09-E4D65A316D6B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38194159-8FB5CC96-4B41-4919-AA09-E4D65A316D6B
Anti-angiogenic agent ramucirumab: meaningful or marginal?
P2860
Q38194159-8FB5CC96-4B41-4919-AA09-E4D65A316D6B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38194159-8FB5CC96-4B41-4919-AA09-E4D65A316D6B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b20f7ca5d91049af42ba12c92793d474b8a3fc89
P2860
Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyr